BEAT:NSD-BioTelemetry, Inc (USD)

COMMON STOCK | Diagnostics & Research | NSD

Last Closing Price

USD 44.85

Change

+0.82 (+1.86)%

Market Cap

USD 1.51B

Volume

0.27M

Average Target Price

USD 47.50 (+5.91%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

BioTelemetry, Inc., a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core laboratory services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in two segments, Healthcare and Research. The Healthcare segment focuses on the remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry services; and event monitoring services, which enable physicians to prescribe wireless event, digital loop event, memory loop event, memory loop event, and non-loop event monitors. It also provides traditional and extended Holter, pacemaker, international normalized ratio, implantable loop recorder, and other implantable cardiac device monitoring services. It serves cardiologists, electrophysiologists, neurologists, and primary care physicians. The Research segment offers laboratory services, such as cardiac monitoring, imaging, scientific consulting, and data management services for drug and medical device trials. Its centralized services comprise electrocardiogram, Holter monitoring, ambulatory blood pressure monitoring, echocardiography, multigated acquisition scan, imaging, protocol development, expert reporting, and statistical analysis. It also provides support services, such as project coordination, setup and management, equipment rental, data transfer, processing, analysis, and 24/7 customer support and site training. The company also focuses on manufacturing, testing, and marketing of cardiac devices and blood glucose monitoring devices, as well as offers contract manufacturing services. BioTelemetry, Inc. was founded in 1994 and is headquartered in Malvern, Pennsylvania. Address: 1000 Cedar Hollow Road, Malvern, PA, United States, 19355

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-28 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ILMN Illumina, Inc

+5.57 (+1.86%)

USD43.89B 61.31 36.64
DXCM DexCom, Inc

-2.17 (-0.54%)

USD38.52B 173.65 108.43
IDXX IDEXX Laboratories, Inc

+8.54 (+2.26%)

USD32.14B 69.09 46.81
EXAS Exact Sciences Corporation

+2.00 (+2.05%)

USD14.67B N/A N/A
GH Guardant Health, Inc

-2.81 (-2.51%)

USD11.12B N/A N/A
ICLR ICON Public Limited Company

+2.90 (+1.58%)

USD9.64B 29.89 20.21
QDEL Quidel Corporation

+1.87 (+0.95%)

USD8.25B 53.92 33.44
PRAH PRA Health Sciences, Inc

+1.86 (+1.91%)

USD6.22B 29.56 17.69
NTRA Natera, Inc

+1.43 (+2.08%)

USD5.77B N/A N/A
SYNH Syneos Health, Inc

+1.81 (+3.51%)

USD5.36B 28.65 16.75

ETFs Containing BEAT

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Diagnostics & Research)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.13% 44% F 55% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.13% 44% F 53% F
Trailing 12 Months  
Capital Gain 10.12% 48% F 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.12% 48% F 64% D
Trailing 5 Years  
Capital Gain 266.42% 80% B- 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 266.42% 80% B- 90% A-
Average Annual (5 Year Horizon)  
Capital Gain 44.24% N/A N/A 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 44.24% N/A N/A 90% A-
Risk Return Profile  
Volatility (Standard Deviation) 54.64% N/A N/A 20% F
Risk Adjusted Return 80.98% N/A N/A 87% B+
Market Capitalization 1.51B 71% C- 75% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Diagnostics & Research)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 80.21 25% F 14% F
Price/Book Ratio 3.79 61% D- 33% F
Price / Cash Flow Ratio 22.28 25% F 14% F
EV/EBITDA 18.10 66% D 39% F
Management Effectiveness  
Return on Equity 5.27% 76% C 64% D
Return on Invested Capital 8.01% 80% B- 73% C
Return on Assets 5.14% 81% B- 85% B
Debt to Equity Ratio 52.01% 31% F 42% F
Technical Ratios  
Short Ratio 12.42 5% F 8% F
Short Percent 18.57% 11% F 11% F
Beta 1.26 46% F 40% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.